Cresco Labs OTC ( (CRLBF) ) has released its Q2 earnings. Here is a breakdown of the information Cresco Labs OTC presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Cresco Labs Inc. is a leading company in the cannabis industry, known for its branded cannabis products and Sunnyside dispensaries, focusing on cultivation, production, and distribution across the United States.
Cresco Labs reported its financial results for the second quarter of 2025, highlighting a solid performance with revenue reaching $164 million and an operating cash flow of $9 million. The company maintained its market share in a competitive environment and announced a significant debt refinancing plan.
Key financial metrics included a gross profit of $83 million, an adjusted gross margin of 50.6%, and an adjusted EBITDA of $41 million with a margin of 25.0%. Despite a net loss of $14 million, largely due to non-cash impairment charges, Cresco Labs retained the top market share position in multiple billion-dollar markets. The company’s strategic move to refinance its debt with a $325 million term loan aims to strengthen its financial foundation.
Looking ahead, Cresco Labs is poised to capitalize on industry consolidation and M&A opportunities, with a focus on sustainable growth. The company remains committed to leveraging its operational model and financial flexibility to navigate the evolving cannabis market landscape.